Abu Dhabi- 7 June 2024- At BIO 2024 International Convention, the Department of Health – Abu Dhabi (DoH) signed a Memorandum of Understanding (MoU) with Novartis Middle East FZE. Under the terms of the MoU, the entities will work together to advance solutions in multiple therapeutic areas. The two priority focus areas include advancing clinical genomics research for real-world evidence (RWE) and generating and disseminating evidence to support the understanding of radioligand therapy (RLT) for cancer patients.
Thierry Diagana, Head of Global Health and California Sites Head at Novartis Biomedical Research, witnessed Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre at DoH, and Ibrahim Aqel, Head of Government Affairs and Value & Access – Gulf at Novartis, sign the MoU.
This collaboration will utilise Abu Dhabi’s genomics expertise as well as its future-forward, agile regulatory framework research hub to collaborate on future clinical research and the generation of RWE. This will include the exploration of innovative solutions and genomics research in oncology, cardiovascular disease, and neuroscience. The two will also work together to generate and disseminate evidence to support the awareness and understanding of RLT – a form of precision nuclear medicine that may recognise and treat disease in patients with advanced cancers – with key stakeholders, including policymakers, healthcare professionals and patient organisations.
Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Center at the at DoH said: “Novartis has been a long-standing partner to the Department of Health, and we are proud to explore these new areas of opportunity to collaborate for the ultimate benefit of patients in the region and beyond. We believe that this partnership will allow us to further accelerate the field of personalised and precision medicine across important therapeutic areas. As we continue to establish Abu Dhabi as a hub for global life science and a centre for innovative research, we are excited to work in synergy with our strategic partners and combine our expertise in the pursuit of common goals.”
Also Read: DOH-Abu Dhabi and Eli Lilly Suisse S.A Partners on Neurodegenerative Disease patient care
Mohamed Ezz Eldin Head of Gulf countries for Novartis, said: “We are thrilled to announce our collaboration with the Department of Health – Abu Dhabi through the signing of this Memorandum of Understanding. This partnership represents a significant milestone in advancing research and innovation in healthcare, particularly in the fields of oncology, cardiovascular diseases, and neuroscience. Novartis commits to supporting the development of clinical research capabilities in Abu Dhabi, generating real-world evidence, and raising awareness about radioligand therapy. We look forward to working closely with the Department of Health – Abu Dhabi to drive innovation and enhance the Health Technology Assessment capabilities in the region. Our goal is to contribute to personalized and precision medicine, ultimately improving patient outcomes.”
